Importance of regulatory T cells in the pathogenesis of psoriasis: Review of the literature

Dermatology

Volumn 227, Issue 2, 2013, Pages 134-145

  Mattozzi, Carlo ^a   Salvi, Monica ^a   D'epiro, Sara ^a   Giancristoforo, Simona ^a   Macaluso, Laura ^a   Luci, Cecilia ^a   Lal, Karan ^a   Calvieri, Stefano ^a   Richetta, Antonio Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Innate immunity; Psoriasis; Regulatory T cells

Indexed keywords

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

HUMANS; IMMUNITY, CELLULAR; PSORIASIS; SKIN; T-LYMPHOCYTES, REGULATORY;

EID: 84888253115     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000353398     Document Type: Review

References (122)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 886-873
2. Salgo R, Thaci D. Treatment of moderate-Tosevere plaque psoriasis. G Ital Dermatol Venereol 2009; 144: 701-711
3. Monteleone G, Pallone F, MacDonald TT, et al. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond) 2010; 120: 1-11
4. Mattozzi C, Richetta AG, Cantisani C, et al. Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR/ CATERPILLER family genes and microbial flora. J Dermatol 2012; 39: 752-760
5. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: S67-S80
6. Gisondi P, Girolomoni G. Biologic therapy in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-519
7. Lima HC, Kimball AB. Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis. Indian J Dermatol 2010; 55: 171-175
8. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10: 849-859
9. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007; 38: 112-121
10. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73
11. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-Tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27
12. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21: 281-285
13. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009; 106: 1903-1908
14. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626-635
15. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol 2008; 29: 429-435
16. Lim, HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 2006; 177: 840-851
17. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108: 4260-4267
18. Zheng SG, Wang J, Wang P, et al. IL-2 is essential for TGF-beta to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007; 178: 2018-2027
19. Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol 2007; 179: 1390ff
20. Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151
21. Joetham A, et al. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. J Immunol 2007; 178: 1433-1442
22. Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, Zhang J, Levy G. The novel CD4+CD25+ regulatory T-cell effector molecule fibrinogen-like protein-2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology 2009; 49: 387-397
23. Grossman WJ, et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104: 2840-2848
24. Deaglio S, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-65
25. Garin MI, Chu CC, Golshayan D, et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109: 2058-2065
26. Read S, Malstrom V, Powrie F. Cytotoxic T lymphocyte associated antigen-4 plays an essential role in the function of CD25+CD4+regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302
27. Workman CJ, Vignali DAA. Neative regulation of T cell homeostasis by LAG-3 (CD223). J Immunol 2004; 174: 688-695
28. Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008; 28: 402-413
29. Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+FOXP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353-1362
30. Shevach EM. Mechanisms of FOXP3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645
31. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 2006; 177: 840-851
32. Fujio K, Okamura T, Yamamoto K. The family of IL-10-secreting CD4+ T cells. Adv Immunol 2010; 105: 99-129
33. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50
34. Beissert S, Schwartz A, Schwartz T. Regulatory T cells. J Invest Dermatol 2006; 126: 15-24
35. Wan YY, Flavell RA: 'Yin-yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol Rev 2007; 220: 199-213
36. Korn T, Bettelli E, Oukka M, et al. IL-17 and TH 17 cells. Annu Rev Immunol 2009; 27: 485-517
37. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 2012; 40: 186-204
38. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787
39. Lourenco EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity 2011; 44: 33-42
40. Ochs HD, Khattri R, Bennett CL, et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome and the Scurfy mutant mouse. Immunol Allergy Clin North Am 2002; 22: 357-368
41. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061
42. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 2003; 112: 1437-1443
43. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J Exp Med 2006; 203: 1701-1711
44. Di Ianni M, Del Papa B, Zei T, et al. T regulatory cell separation for clinical application. Transfus Apher Sci 2012; 47: 213-216
45. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol 2007; 19: 176-185
46. Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009; 206: 1853-1862
47. Yates J, Rovis F, Mitchell P, et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 2007; 19: 785-799
48. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532
49. Yang J, Brook MO, Carvalho-Gaspar M, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci USA 2007; 104: 19954-19959
50. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004; 172: 3580-3589
51. Choi BK, Bae JS, Choi EM, et al: 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004; 75: 785-791
52. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-697
53. Clough LE, Wang CJ, Schmidt EM, et al. Release from regulatory T cell-mediated suppression during the onset of tissue specific autoimmunity is associated with elevated IL-21. J Immunol 2008; 180: 5393-5401
54. Tang Q, Henriksen KJ, Bi M, et al. In vitroexpanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 1455-1465
55. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140
56. Putnam AL, Vendrame F, Dotta F, et al. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005; 24: 55-62
57. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4+CD25+ Tcells from patients with type 1 diabetes. Diabetes 2005; 54: 92-99
58. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T cells of type 1 diabetic subjects. Diabetes 2010; 59: 407-415
59. Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155: 173-181
60. Schneider A, Rieck M, Sanda S, et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+FOXP3+ regulatory T cells. J Immunol 2008; 181: 7350-7355
61. Lawson JM, Tremble J, Dayan C, et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008; 154: 353-359
62. Kohm AP, Carpentier PA, Anger HA, et al. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 4712-4716
63. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979
64. Putheti P, Pettersson A, Soderstrom M, et al. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol 2004; 24: 155-161
65. Feger U, Luther C, Poeschel S, et al. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147: 412-418
66. Kumar M, Putzki N, Limmroth V, et al. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006; 180: 178-184
67. De Andres C, Aristimuno C, de Las Heras V, et al. Interferon β-1a therapy enhances CD4+regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007; 182: 204-211
68. Venken K, Hellings N, Thewissen M, et al. Compromised CD4+ CD25high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the singlecell level. Immunology 2007; 123: 79-89
69. Haas J, Fritzsching B, Trubswetter P, et al. Prevalence of newly generated naive regulatory T cells (T reg) is critical for T reg suppressive function and determines T reg dysfunction in multiple sclerosis. J Immunol 2007; 179: 1322-1330
70. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ T reg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232
71. Michel L, Berthelot L, Pettre S, et al. Patients with relapsing-remitting multiple sclerosis have normal T reg function when cells expressing IL-7 receptor α-chain are excluded from the analysis. J Clin Invest 2008; 118: 3411-3419
72. Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35: 3343-3352
73. Astier AL, Meiffren G, Freeman S, et al. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006; 116: 3252-3257
74. Gerli R, Nocentini G, Alunno A, et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009; 8: 426-430
75. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003; 21: 273-276
76. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175: 8392-8400
77. Suen JL, Li HT, Jong YJ, et al. Altered homeostasis of CD4+ FoxP3+ regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009; 127: 196-205
78. Valencia X, Yarboro C, Illei G, et al. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-2588
79. Yan B, Ye S, Chen G, et al. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α-producing antigen-presenting cells. Arthritis Rheum 2008; 58: 801-812
80. Yates J, Whittington A, Mitchell P, et al. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008; 153: 44-55
81. Venigalla RK, Tretter T, Krienke S, et al. Reduced CD4+, CD25 - T cell sensitivity to the suppressive function of CD4+, CD25high, CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2120-2130
82. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, et al. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008; 17: 289-294
83. Cao D, Malmstrom V, Baecher-Allan C, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003; 33: 215-223
84. Mottonen M, Heikkinen J, Mustonen L, et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140: 360-367
85. Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology 2006; 45: 1210-1217
86. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277-285
87. Flores-Borja F, Jury EC, Mauri C, et al. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008; 105: 19396-19401
88. Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007; 125: 281-290
89. Takahashi M, Nakamura K, Honda K, et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 2006; 51: 677-686
90. Maul J, Mabarrack N, Barbour A, et al. Peripheral and intestinal regulatory CD4+ CD-25high T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-1878
91. Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010; 16: 1299-1310
92. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30: 80-89
93. Kelsen J, Agnholt J, Hoffmann HJ, et al. FoxP3+CD4+CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol 2005; 141: 549-557
94. Makita S, Kanai T, Nemoto Y, et al. Intestinal lamina propria retaining CD4+CD25+regulatory T cells is a suppressive site of intestinal inflammation. J Immunol 2007; 178: 4937-4946
95. Fantini MC, Rizzo A, Fina D, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009; 136: 1308-1316
96. Quaglino P, Antiga E, Comessatti A, et al. Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. Arch Dermatol Res 2012; 304: 639-645
97. Antiga E, Quaglino P, Bellandi S, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010; 162: 1056-1063
98. Banica L, Besliu A, Pistol G, et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009; 42: 41-49
99. Antiga E, Kretz CC, Klembt R. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 2010; 35: 342-350
100. Sather BD, Treuting P, Perdue N, et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007; 204: 1335-1347
101. Hirahara K, Liu L, Clark RA, et al. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177: 4488-4494
102. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-1383
103. Zhang L, Yang XQ, Cheng J, et al. Increased Th17 cells are accompanied by FoxP3(+) T reg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 2010; 135: 108-117
104. Zhang K, Li X, Yin G, et al. Functional characterization of CD4+CD25+ regulatory T cells differentiated in vitro from bone marrow-derived haematopoietic cells of psoriasis patients with a family history of the disorder. Br J Dermatol 2008; 158: 298-305
105. Shehata IH, Elghandour TM. A possible pathogenic role of CD4+ CD25+ T-regulatory cells in psoriasis . Egypt J Immunol 2007; 14: 21-31
106. Bovenschen HJ, van Vlijmen-Willems IM, van de Kerkhof PC, et al. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 2006; 213: 111-117
107. Fujimura T, Okuyama R, Ito Y, Aiba S. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008; 158: 1256-1263
108. Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs guttate psoriasis vulgaris. Br J Dermatol 2010; 163: 48-56
109. Chen L, Shen Z, Wang G, et al. Dynamic frequency of CD4+CD25+Foxp3+ T reg cells in psoriasis vulgaris. J Dermatol Sci 2008; 51: 200-203
110. Richetta AG, Mattozzi C, Salvi M, et al. CD4+ CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement. Eur J Dermatol 2011; 21: 344-348
111. Quaglino P, Ortoncelli M, Comessatti A, et al. Circulating CD4+CD25brightFOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 2009; 219: 250-258
112. Diluvio L, Romiti ML, Angelini F, et al. Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis. Br J Dermatol 2010; 162: 895-897
113. Quaglino P, Bergallo M, Ponti R, et al. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology 2011; 223: 57-67
114. Richetta AG, Mattozzi C, Salvi M, et al. Downregulation of circulating CD4(+) CD25(bright) Foxp3(+) T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases. Int J Dermatol, E-pub ahead of print
115. Hess AD, Colombani PM, Esa AH. Cyclosporine and the immune response: basic aspects. Crit Rev Immunol 1986; 6: 123-149
116. Shintani Y, Yasuda Y, Kobayashi K, et al. Narrowband ultraviolet B radiation suppresses contact hypersensitivity. Photodermatol Photoimmunol Photomed 2008; 24: 32-37
117. Saito C, Maeda A, Morita A. Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis. J Dermatol Sci 2009; 53: 231-233
118. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174: 164-173
119. Goodman WA, Levine AD, Massari JV, et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183: 3170-3176
120. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cellmediated suppression by dendritic cells. Science 2003; 299: 1033-1036
121. Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44-56
122. Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011; 131: 1853-1860